Exploring the Enigma: Understanding Ehlers-Danlos Syndrome, Type 4

Medically reviewed by Brandon Colby, MD, last reviewed Oct 16, 2026

Short answer: Vascular Ehlers-Danlos syndrome (type 4, or vEDS) is mainly caused by changes in the COL3A1 gene. Genetic testing of COL3A1 can confirm the diagnosis and tell it apart from other types of Ehlers-Danlos syndrome. This matters because vEDS can cause arterial and organ rupture, so an early diagnosis guides careful monitoring.

Update coming in December 2026: The criteria used to diagnose Ehlers-Danlos syndrome (EDS) and hypermobility spectrum disorders (HSD) are being updated for the first time since 2017. If you already have a diagnosis, you do not need to be reevaluated just because the classification is changing. Read our EDS diagnostic criteria update to see what changes for you.

Ehlers-Danlos Syndrome, Type 4, also known as Vascular Ehlers-Danlos Syndrome (vEDS), is a rare genetic disorder that can have profound implications on an individual's health. Characterized by fragile blood vessels, thin skin, and joint hypermobility, vEDS poses unique challenges in terms of diagnosis and management. In recent years, genetic testing has emerged as a valuable tool in the identification and understanding of this complex condition.

Decoding Vascular Ehlers-Danlos Syndrome

Vascular Ehlers-Danlos Syndrome is one of the most severe forms of the Ehlers-Danlos syndromes, a group of connective tissue disorders. The condition is primarily caused by mutations in the COL3A1 gene, which encodes for type III collagen, an essential component of blood vessel walls and other tissues. Individuals with vEDS often experience life-threatening complications such as arterial rupture, organ rupture, and severe internal bleeding. Early diagnosis is crucial to manage and mitigate the risks associated with this disorder.

The Role of Genetic Testing in vEDS Diagnosis

Genetic testing plays a pivotal role in the diagnosis of vEDS. By analyzing the COL3A1 gene, healthcare providers can confirm the presence of mutations that cause the disorder. This confirmation is critical for distinguishing vEDS from other types of Ehlers-Danlos syndromes and connective tissue disorders, which may have overlapping symptoms but require different management strategies.

Genetic Testing for Family Planning

For families affected by vEDS, genetic testing offers invaluable insights for family planning. Since vEDS is inherited in an autosomal dominant pattern, there is a 50% chance that an affected parent will pass the mutation to their offspring. Genetic counseling can help prospective parents understand the risks and make informed decisions about family planning. Prenatal testing and preimplantation genetic diagnosis are options that can be considered to prevent the transmission of vEDS to future generations.

Guiding Personalized Management Plans

Once a diagnosis of vEDS is confirmed through genetic testing, healthcare providers can tailor management plans to the individual's specific needs. Regular monitoring of the cardiovascular system, along with lifestyle modifications and avoidance of activities that may increase the risk of vascular injury, are crucial components of management. Genetic testing results can also inform the use of medications that may help stabilize blood vessel walls and reduce the risk of complications.

Facilitating Research and Understanding

Genetic testing not only benefits individuals and families but also contributes to the broader understanding of vEDS. By identifying specific mutations and their effects, researchers can gain insights into the pathophysiology of the disorder. This knowledge can drive the development of targeted therapies and interventions that may improve the quality of life for those living with vEDS.

Conclusion: The Impact of Genetic Testing on vEDS

In summary, genetic testing has revolutionized the approach to diagnosing and managing Vascular Ehlers-Danlos Syndrome. By providing a definitive diagnosis, informing family planning decisions, guiding personalized care, and advancing research, genetic testing is an indispensable tool in tackling the challenges posed by this enigmatic disorder. As our understanding of vEDS continues to evolve, genetic testing will undoubtedly remain at the forefront of efforts to improve outcomes for affected individuals and their families.

What Is the December 2026 EDS Diagnostic Criteria Update?

The Ehlers-Danlos Society is expected to publish an updated classification framework for the Ehlers-Danlos syndromes and hypermobility spectrum disorders in December 2026, the first major update since 2017. If you already have a diagnosis, you do not need to be reevaluated solely because the classification is changing. See how Sequencing is preparing in our guide to the EDS classification update.

Research on Hypermobile EDS and Dysautonomia

Sequencing and the Norris Lab at the Medical University of South Carolina have opened a research study on hypermobile EDS (hEDS) and dysautonomia. If you already have whole genome sequencing with Sequencing, you can choose whether to take part. Participation is voluntary, data is de-identified, and individual results are not returned. Read why we are launching our patient driven genetic study for hypermobile Ehlers-Danlos syndrome and dysautonomia.

Get Tested With Whole Genome Sequencing

Whole genome sequencing reads 100% of your DNA, which includes the COL3A1 gene. Sequencing's Kit Bundles include a Whole Genome Sequencing kit and Next Gen Disease Screening, which analyzes your genome for more than 15,000 conditions. Bring your results to a doctor who knows connective tissue disorders.

Shop All Whole Genome Sequencing Kit Bundles

Frequently Asked Questions About Vascular Ehlers-Danlos Syndrome

What is vascular Ehlers-Danlos syndrome (vEDS)?

Vascular Ehlers-Danlos syndrome, also called Ehlers-Danlos syndrome type 4, is a rare genetic disorder with fragile blood vessels, thin skin and joint hypermobility. It is one of the most severe forms of Ehlers-Danlos syndrome.

What causes vEDS?

It is mainly caused by changes in the COL3A1 gene, which makes type III collagen. Type III collagen is an important part of blood vessel walls and other tissues.

What complications can vEDS cause?

People with vEDS can have life threatening complications such as arterial rupture, organ rupture and severe internal bleeding. Early diagnosis is important to manage these risks.

Can genetic testing diagnose vEDS?

Yes. Testing the COL3A1 gene can confirm the changes that cause vEDS. This is important for telling vEDS apart from other types of Ehlers-Danlos syndrome and connective tissue disorders that have overlapping symptoms but need different management.

Is vEDS inherited?

vEDS is inherited in an autosomal dominant pattern, so a parent who has it has a 50% chance of passing the change to each child. Genetic counseling can help families understand their options, including prenatal testing and preimplantation genetic diagnosis.

How is vEDS managed?

Care is tailored to the person. It usually includes regular monitoring of the heart and blood vessels, lifestyle changes and avoiding activities that raise the risk of blood vessel injury. Some medicines may help support blood vessel walls. A doctor who knows vEDS should guide care.

Does Sequencing test for vEDS?

Sequencing's whole genome sequencing reads 100% of your DNA, which includes the COL3A1 gene. Bring your results to a doctor or genetic counselor who can explain what they mean for you.

References

Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40-47. doi:10.1002/ajmg.c.31553
Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. doi:10.1002/ajmg.c.31552

This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. Talk to a qualified healthcare provider about your own health.